Skip to main content
Foundayo product image

Foundayo

VS
Wegovy Pill product image

Wegovy Pill

Head-to-Head Comparison

Foundayo vs. Wegovy Pill

Foundayo can be taken any time without food or water restrictions, while oral Wegovy has specific timing requirements. Pricing and insurance coverage are still evolving for both.

Key Metrics

Foundayo

Foundayo

Wegovy Pill

Wegovy Pill

Monthly Cost
$149–$349/mo
$149–$299/mo (NovoCare)
FDA Approval

Weight Management (April 2026)

Weight Management (2025)

Mechanism

GLP-1 Receptor Agonist (non-peptide)

GLP-1 Receptor Agonist (peptide-based oral)

Mean Weight Loss

~12.4% (ATTAIN-1, 36mg)

~13.6% (OASIS 4, 25mg)

Foundayo

Key Advantages

  • Take any time of day — no food or water restrictions
  • Non-peptide small molecule (different drug class)
  • $25/mo with Lilly savings card

Wegovy Pill

Key Advantages

  • Slightly higher weight loss in trials (~13.6% vs ~12.4%)
  • Longer clinical track record (semaglutide class)
  • More established insurance pathways

Trusted Telehealth Providers

Safety first. Access genuine medications through verified medical platforms with board-certified clinical supervision.

Henry Meds logo
TOP RATED

Henry Meds

Specializing in transparent, monthly subscription models for compounded options.

Starts At $297/mo
Visit Provider
Hims logo

Hims

Streamlined digital-first experience with competitive all-in pricing.

Starts At $297/mo
Visit Provider
Ro logo

Ro Weight Loss

White-glove concierge insurance support for brand-name GLP-1 therapy.

Starts At $145/mo*
Visit Provider

Overview

Two oral GLP-1 pills are now available for weight loss. Foundayo (orforglipron) from Eli Lilly and the Wegovy pill (oral semaglutide) from Novo Nordisk.

Key Differences

FactorFoundayoWegovy Pill
Generic NameOrforglipronSemaglutide
FDA ApprovalApril 20262025
ManufacturerEli LillyNovo Nordisk
Monthly Cost$149–$349/mo$149–$299/mo (NovoCare)
Savings Programs$25/mo with Lilly savings card$149/mo starter via NovoCare
DosingOnce daily, any timeOnce daily, empty stomach
Food RestrictionsNoneMust fast 30 min after taking
Mean Weight Loss~12.4% (ATTAIN-1)~13.6% (OASIS 4)
MechanismNon-peptide GLP-1 agonistPeptide-based oral GLP-1 agonist

Convenience Factor

Foundayo’s biggest advantage is convenience. You can take it at any time of day, with or without food, and without water restrictions. The Wegovy pill requires an empty stomach, a small sip of water (≤4 oz), and a 30-minute fast after taking it. For many patients, this daily routine difference matters more than small differences in efficacy data.

Clinical Data

Foundayo (ATTAIN-1): 12.4% mean weight loss at 36mg over 72 weeks. 59.6% of participants lost ≥10% body weight. 39.6% lost ≥15%.

Wegovy Pill (OASIS 4): 13.6% mean weight loss at 25mg over 64 weeks. 60% of participants lost ≥10% body weight. 47% lost ≥15%.

Pricing Comparison

Both medications are priced competitively for the oral GLP-1 market. Foundayo can drop to $25/mo with the Lilly savings card (with qualifying insurance). Wegovy Pill starts at $149/mo through NovoCare. Without savings programs, both retail in the $149–$349/mo range — dramatically cheaper than injectable options.

How It Compares

Frequently Asked Questions

Which oral GLP-1 pill is more effective?

Wegovy Pill showed slightly higher average weight loss in clinical trials — approximately 13.6% in OASIS 4 at the 25 mg dose over 64 weeks, compared to 12.4% in ATTAIN-1 for Foundayo at 36 mg over 72 weeks. However, these were separate trials with different populations, durations, and protocols — not a direct head-to-head comparison. The ~1.2% difference may not reflect a true pharmacological advantage. When looking at treatment completers in OASIS 4, Wegovy Pill showed 16.6% weight loss, and Foundayo’s ATTAIN-1 showed 59.6% of participants losing at least 10% body weight — suggesting meaningful efficacy for both. Real-world outcomes depend heavily on adherence: Foundayo’s no-restriction dosing may translate to better real-world adherence for some patients, potentially closing or reversing the trial-measured gap. Individual results vary significantly based on diet, activity, and consistency of use. The most effective drug is the one you take correctly every day.

Can I take Foundayo with food?

Yes — and this is Foundayo’s most clinically significant practical advantage. Foundayo (orforglipron) is the only oral GLP-1 that can be taken at any time of day, with or without food, without any water restrictions. This flexibility is possible because orforglipron is a non-peptide small molecule — it’s chemically stable in digestive environments and doesn’t require special stomach conditions to absorb. By contrast, Wegovy Pill (oral semaglutide) must be taken on an empty stomach with no more than 4 oz of plain water, followed by a 30-minute fast before eating or drinking anything. This fasting requirement is essential for Wegovy Pill’s absorption via its SNAC excipient formulation, which temporarily alters stomach pH. In the ATTAIN-1 trial supporting Foundayo’s FDA approval, participants took the medication with no meal restrictions and still achieved 12.4% mean weight loss. For patients who struggle with strict morning routines, travel frequently, or have irregular schedules, Foundayo’s flexibility represents a genuine quality-of-life improvement.

Which is cheaper?

Both Foundayo and Wegovy Pill are competitively priced at $149–$349/month, making them the most affordable brand-name GLP-1 weight-loss options currently available as of April 2026. Foundayo can be as low as $25/month with the Eli Lilly savings card for patients with qualifying commercial insurance — potentially the cheapest branded GLP-1 at that copay level. Without insurance, Foundayo’s list price is approximately $149/month. Wegovy Pill starts at $149/month through NovoCare for the starter dose and rises toward $299/month at higher doses. For patients without insurance and without savings card eligibility, both retail in the $149–$349 range. For context, injectable Wegovy runs $349/month through NovoCare and Zepbound runs $299–$449/month through LillyDirect — meaning oral options are genuinely the more affordable branded pathway. Both offer substantially better pricing transparency than the pre-2026 era when most patients relied on compounded alternatives.

Keep Reading

Frequently Asked Questions

Which oral GLP-1 pill is more effective?
Wegovy Pill showed slightly higher average weight loss in clinical trials — approximately 13.6% in OASIS 4 at the 25 mg dose over 64 weeks, compared to 12.4% in ATTAIN-1 for Foundayo at 36 mg over 72 weeks. However, these were separate trials with different populations, durations, and protocols — not a direct head-to-head comparison. The ~1.2% difference may not reflect a true pharmacological advantage. When looking at treatment completers in OASIS 4, Wegovy Pill showed 16.6% weight loss, and Foundayo's ATTAIN-1 showed 59.6% of participants losing at least 10% body weight — suggesting meaningful efficacy for both. Real-world outcomes depend heavily on adherence: Foundayo's no-restriction dosing may translate to better real-world adherence for some patients, potentially closing or reversing the trial-measured gap. Individual results vary significantly based on diet, activity, and consistency of use. The most effective drug is the one you take correctly every day.
Can I take Foundayo with food?
Yes — and this is Foundayo's most clinically significant practical advantage. Foundayo (orforglipron) is the only oral GLP-1 that can be taken at any time of day, with or without food, without any water restrictions. This flexibility is possible because orforglipron is a non-peptide small molecule — it's chemically stable in digestive environments and doesn't require special stomach conditions to absorb. By contrast, Wegovy Pill (oral semaglutide) must be taken on an empty stomach with no more than 4 oz of plain water, followed by a 30-minute fast before eating or drinking anything. This fasting requirement is essential for Wegovy Pill's absorption via its SNAC excipient formulation, which temporarily alters stomach pH. In the ATTAIN-1 trial supporting Foundayo's FDA approval, participants took the medication with no meal restrictions and still achieved 12.4% mean weight loss. For patients who struggle with strict morning routines, travel frequently, or have irregular schedules, Foundayo's flexibility represents a genuine quality-of-life improvement.
Which is cheaper?
Both Foundayo and Wegovy Pill are competitively priced at $149–$349/month, making them the most affordable brand-name GLP-1 weight-loss options currently available as of April 2026. Foundayo can be as low as $25/month with the Eli Lilly savings card for patients with qualifying commercial insurance — potentially the cheapest branded GLP-1 at that copay level. Without insurance, Foundayo's list price is approximately $149/month. Wegovy Pill starts at $149/month through NovoCare for the starter dose and rises toward $299/month at higher doses. For patients without insurance and without savings card eligibility, both retail in the $149–$349 range. For context, injectable Wegovy runs $349/month through NovoCare and Zepbound runs $299–$449/month through LillyDirect — meaning oral options are genuinely the more affordable branded pathway. Both offer substantially better pricing transparency than the pre-2026 era when most patients relied on compounded alternatives.
Affiliate Disclosure: GLP-1 Price Guide may receive a commission if you choose to utilize the services or tools linked on this page. Our research team maintains strict editorial independence to ensure objective pricing data.